Neocellularization and neovascularization of nanosized bioactive glass-coated decellularized trabecular bone scaffolds

Gerhardt L. -. , WIDDOWS K. L. , EROL M. M. , NANDAKUMAR A., ROQAN I. S. , ANSARI T., ...Daha Fazla

JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, cilt.101, sa.3, ss.827-841, 2013 (SCI İndekslerine Giren Dergi) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 101 Konu: 3
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1002/jbm.a.34373
  • Sayfa Sayıları: ss.827-841


In this study, the in vivo recellularization and neovascularization of nanosized bioactive glass (n-BG)-coated decellularized trabecular bone scaffolds were studied in a rat model and quantified using stereological analyses. Based on the highest amount of vascular endothelial growth factor (VEGF) secreted by human fibroblasts grown on n-BG coatings (01.245 mg/cm2), decellularized trabecular bone samples (porosity: 4381%) were coated with n-BG particles. Grown on n-BG particles at a coating density of 0.263 mg/cm2, human fibroblasts produced 4.3 times more VEGF than on uncoated controls. After 8 weeks of implantation in SpragueDawley rats, both uncoated and n-BG-coated samples were well infiltrated with newly formed tissue (4748%) and blood vessels (34%). No significant differences were found in cellularization and vascularization between uncoated bone scaffolds and n-BG-coated scaffolds. This finding indicates that the decellularized bone itself may exhibit growth-promoting properties induced by the highly interconnected pore microarchitecture and/or proteins left behind on decellularized scaffolds. Even if we did not find proangiogenic effects in n-BG-coated bone scaffolds, a bioactive coating is considered to be beneficial to impart osteoinductive and osteoconductive properties to decellularized bone. n-BG-coated bone grafts have thus high clinical potential for the regeneration of complex tissue defects given their ability for recellularization and neovascularization. (C) 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 101A: 827-841, 2013.